Harrow (NASDAQ:HROW) Announces Earnings Results

Key Points

• Harrow reported quarterly EPS of $0.25, beating the $0.19 analyst consensus by $0.06; revenue was $99.3 million versus expectations of $98.59 million.
• Despite the earnings beat, the company posted a negative net margin of 13.51% and negative return on equity of 38.00%. Shares rose 2.2% to $27.47 during Monday’s trading.
• Analysts’ consensus rating is Moderate Buy, with a $66.17 average price target. One insider also sold 11,250 shares at $40 each, halving their position.

Harrow (NASDAQ:HROW - Get Free Report) released its quarterly earnings data on Monday. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.06, FiscalAI reports. The company had revenue of $99.30 million during the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%.

Harrow Trading Up 2.2%

Shares of Harrow stock traded up $0.58 during mid-day trading on Monday, hitting $27.47. The stock had a trading volume of 1,162,138 shares, compared to its average volume of 691,479. The firm has a 50-day moving average of $31.63 and a two-hundred day moving average of $37.91. The firm has a market cap of $1.03 billion, a P/E ratio of -27.47 and a beta of 0.18. The company has a quick ratio of 2.08, a current ratio of 2.24 and a debt-to-equity ratio of 19.70. Harrow has a 12-month low of $25.76 and a 12-month high of $54.85.

Analyst Ratings Changes

HROW has been the subject of a number of analyst reports. Leerink Partners started coverage on Harrow in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 price target for the company. Wall Street Zen upgraded Harrow from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Zacks Research downgraded Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday, November 3rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Harrow in a report on Friday, October 16th. Finally, BTIG Research reiterated a "buy" rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Harrow currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.17.

Insider Activity at Harrow

In other news, insider Amir Shojaei sold 11,250 shares of Harrow stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the sale, the insider owned 11,250 shares of the company's stock, valued at approximately $450,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.80% of the company's stock.

Harrow Company Profile

Harrow, Inc is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription therapies for eye care. The company's portfolio addresses conditions and procedures involving the ocular surface, anterior segment, and retina, with products intended for use by ophthalmologists and other eye-care professionals.

Harrow's commercial products include VEVYE, a cyclosporine ophthalmic solution for the treatment of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during ophthalmic procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.